MX2020002437A - Composicion farmaceutica para el suministro de peptidos. - Google Patents

Composicion farmaceutica para el suministro de peptidos.

Info

Publication number
MX2020002437A
MX2020002437A MX2020002437A MX2020002437A MX2020002437A MX 2020002437 A MX2020002437 A MX 2020002437A MX 2020002437 A MX2020002437 A MX 2020002437A MX 2020002437 A MX2020002437 A MX 2020002437A MX 2020002437 A MX2020002437 A MX 2020002437A
Authority
MX
Mexico
Prior art keywords
combination
peptide
metal
delivery
pharmaceutical compositions
Prior art date
Application number
MX2020002437A
Other languages
English (en)
Inventor
Bhushan Dhruvkumar Desai
Siegfried Gschliesser
Original Assignee
Anya Biopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anya Biopharm Inc filed Critical Anya Biopharm Inc
Publication of MX2020002437A publication Critical patent/MX2020002437A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que incluye: una cantidad farmacéuticamente efectiva de al menos un péptido; y una cantidad farmacéuticamente aceptable de una combinación de: a) al menos un metal en forma de cualquiera o una combinación de una sal y un complejo del mismo; y b) al menos un agente reductor, en el que se selecciona al menos un metal de cualquiera o una combinación de: vanadio, cromo y manganeso, y en el que la combinación de a) al menos un metal en forma de cualquiera o una combinación de una sal y un complejo y b) al menos un agente reductor ofrece protección, al menos en parte, al menos un péptido de la degradación proteolítica al ingerirlo.
MX2020002437A 2017-09-21 2018-09-19 Composicion farmaceutica para el suministro de peptidos. MX2020002437A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201711033555 2017-09-21
PCT/IB2018/057209 WO2019058273A1 (en) 2017-09-21 2018-09-19 PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF A PEPTIDE

Publications (1)

Publication Number Publication Date
MX2020002437A true MX2020002437A (es) 2020-07-14

Family

ID=65810723

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002437A MX2020002437A (es) 2017-09-21 2018-09-19 Composicion farmaceutica para el suministro de peptidos.

Country Status (21)

Country Link
US (2) US11389474B2 (es)
EP (1) EP3509573B1 (es)
JP (3) JP7744741B2 (es)
KR (1) KR102542671B1 (es)
CN (1) CN109843274A (es)
AU (1) AU2018336135B2 (es)
CL (1) CL2020000440A1 (es)
DK (1) DK3509573T3 (es)
EA (1) EA202090317A1 (es)
ES (1) ES2951918T3 (es)
HR (1) HRP20230799T1 (es)
HU (1) HUE062587T2 (es)
IL (1) IL273451B2 (es)
MX (1) MX2020002437A (es)
PL (1) PL3509573T3 (es)
PT (1) PT3509573T (es)
SG (1) SG11201901402PA (es)
SI (1) SI3509573T1 (es)
TW (1) TWI751379B (es)
WO (1) WO2019058273A1 (es)
ZA (1) ZA202001393B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI751379B (zh) * 2017-09-21 2022-01-01 奧孟亞股份有限公司 用於遞送胜肽之藥物組合物
EP3886814B1 (en) 2018-11-26 2025-02-19 The Procter & Gamble Company Solid pharmaceutical preparation containing lipoic acid and use thereof
KR20210137373A (ko) * 2019-03-08 2021-11-17 안야 바이오팜 인코포레이티드 부갑상샘 호르몬 유사체의 경구 제제 및 치료
KR102216578B1 (ko) * 2019-09-05 2021-02-17 주식회사 아이큐어비앤피 테리파라타이드를 포함하는 경구용 약학 조성물 및 이의 제조방법
KR102253318B1 (ko) * 2020-06-02 2021-05-18 (주)위바이오트리 금속 상 변환 화합물 및 이의 제조 방법
EP4226918A1 (en) * 2022-02-15 2023-08-16 Filip Majewski Pharmaceutical single dosage form for oral delivery of peptides
WO2025037993A1 (en) 2023-08-13 2025-02-20 Filip Majewski Dosage form for peptide agents
US20260077020A1 (en) * 2025-09-26 2026-03-19 Danielle Marie Le Roux Oral peptide pharmaceutical composition that facilitates enhanced oral absorption

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
US20060134226A1 (en) * 2004-11-16 2006-06-22 Todd Leonard Compositions useful to treat ocular neovascular diseases and macular degeneration
WO2007029238A2 (en) 2005-09-06 2007-03-15 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
EP1800675B1 (en) 2005-12-23 2011-05-18 N.V. Nutricia Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia
EP2654777A4 (en) * 2010-12-21 2014-07-09 Nestec Sa METHOD AND COMPOSITIONS FOR ADMINISTERING THE BLOOD SUGAR IN ANIMALS
EP2696847A1 (en) 2011-04-14 2014-02-19 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
CN103861086A (zh) * 2014-03-07 2014-06-18 东营倍康生物科技有限公司 一种苦瓜肽阿拉伯糖复合片的制作方法
ES2630106T3 (es) * 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
JP2018529749A (ja) * 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
TWI751379B (zh) * 2017-09-21 2022-01-01 奧孟亞股份有限公司 用於遞送胜肽之藥物組合物

Also Published As

Publication number Publication date
KR20200056954A (ko) 2020-05-25
JP2024111060A (ja) 2024-08-16
DK3509573T3 (da) 2023-08-14
ES2951918T3 (es) 2023-10-25
HRP20230799T1 (hr) 2023-11-10
US20200121796A1 (en) 2020-04-23
AU2018336135B2 (en) 2024-06-06
JP2021506731A (ja) 2021-02-22
EA202090317A1 (ru) 2020-06-02
KR102542671B1 (ko) 2023-06-12
IL273451A (en) 2020-05-31
TW201919683A (zh) 2019-06-01
HUE062587T2 (hu) 2023-11-28
US12208118B2 (en) 2025-01-28
CA3072864A1 (en) 2019-03-28
WO2019058273A1 (en) 2019-03-28
TWI751379B (zh) 2022-01-01
US20220288111A1 (en) 2022-09-15
US11389474B2 (en) 2022-07-19
PT3509573T (pt) 2023-08-07
CL2020000440A1 (es) 2020-08-07
PL3509573T3 (pl) 2023-10-16
JP7744741B2 (ja) 2025-09-26
EP3509573B1 (en) 2023-05-24
JP2022132375A (ja) 2022-09-08
SG11201901402PA (en) 2019-04-29
SI3509573T1 (sl) 2023-10-30
EP3509573A4 (en) 2020-04-29
AU2018336135A1 (en) 2020-02-06
IL273451B1 (en) 2023-01-01
ZA202001393B (en) 2020-10-28
CN109843274A (zh) 2019-06-04
BR112020005363A2 (pt) 2020-09-24
NZ760995A (en) 2024-10-25
EP3509573A1 (en) 2019-07-17
IL273451B2 (en) 2023-05-01

Similar Documents

Publication Publication Date Title
MX2020002437A (es) Composicion farmaceutica para el suministro de peptidos.
WO2021217004A3 (en) Methods and compositions for treating virus-associated inflammation
HK1247822A1 (zh) 用於活性剂口服给药的制剂
HK1251466A1 (zh) 包含pi3k抑制剂和hdac抑制剂的组合物
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
WO2017044894A3 (en) Cartilage-homing peptides
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
WO2015157469A3 (en) Polypeptide compositions with type vii collagen fibronectin type iii- like repeats and treatment methods for wound closure and healing
PH12022550448A1 (en) Niclosamide delayed-release composition and antiviral use thereof
PH12014502512A1 (en) Topical pharmaceutical compositions comprising terbinafine and urea
ZA202201560B (en) Liquid dressing compositions and their veterinary uses
MX369571B (es) Composicion para prevenir o tratar enfermedades del higado graso.
JOP20210230A1 (ar) صياغات صيدلانية
EP3937905A4 (en) RINSING COMPOSITIONS AND THEIR USES FOR THE ADMINISTRATION OF ACTIVE AGENTS
MX2023013577A (es) Composiciones de bismuto-tiol y metodos de uso.
TR201713929A2 (tr) Ki̇tosan ve alji̇natin hemostati̇k kompozi̇syonlari
MY197527A (en) Preventive and curative peroxometallate based composition, notably pharmaceutical composition
PH12020551100A1 (en) Bowel cleansing composition
NZ755637A (en) Compounds and their use in the treatment of schistosomiasis
PH12016501548B1 (en) Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
EA201800266A1 (ru) Антивирусная фармацевтическая композиция
PH12021551086A1 (en) Pharmaceutical formulations of cyclosporine analogs
MX2019009235A (es) Compuestos antifibroticos.
MX2021005944A (es) Inhibidores de rip1.
MX2024006105A (es) Nitroxolina para su uso en el tratamiento o prevencion de un neurofibroma plexiforme.